FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Patricia Fournier

Research Profile

Disorders

Chemicals & Drugs

Concepts & Ideas

Procedures

Antineoplastic Combined Chemotherapy Protocols

Activities & Behaviors

Life Tables

Co-author Network

Publications

TOP 3
Bret Taback; Steven J O'Day; Peter D Boasberg; Sherry Shu; Patricia Fournier; Robert Elashoff; He-Jing Wang; Dave S B Hoon
Circulating DNA microsatellites: molecular determinants of response to biochemotherapy in patients with metastatic melanoma.
Steven J O'Day; Peter D Boasberg; Lawrence Piro; Timothy S Kristedja; He-Jing Wang; Maureen Martin; Regina Deck; Patricia Ames; Kelly Shinn; Hannah Kim; Patricia Fournier; Guy Gammon
Maintenance biotherapy for metastatic melanoma with interleukin-2 and granulocyte macrophage-colony stimulating factor improves survival for patients responding to induction concurrent biochemotherapy.
Steven J O'Day; Peter D Boasberg; Timothy S Kristedja; Maureen Martin; He-Jing Wang; Patricia Fournier; M Cabot; Michael W DeGregorio; Guy Gammon
High-dose tamoxifen added to concurrent biochemotherapy with decrescendo interleukin-2 in patients with metastatic melanoma.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Patricia Fournier (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2004: Bret Taback; Steven J O'Day; Peter D Boasberg; Sherry Shu; Patricia Fournier; Robert Elashoff; He-Jing Wang; Dave S B Hoon
Circulating DNA microsatellites: molecular determinants of response to biochemotherapy in patients with metastatic melanoma.
Journal of the National Cancer Institute 2004;96(2):152-6.
2002: Steven J O'Day; Peter D Boasberg; Lawrence Piro; Timothy S Kristedja; He-Jing Wang; Maureen Martin; Regina Deck; Patricia Ames; Kelly Shinn; Hannah Kim; Patricia Fournier; Guy Gammon
Maintenance biotherapy for metastatic melanoma with interleukin-2 and granulocyte macrophage-colony stimulating factor improves survival for patients responding to induction concurrent biochemotherapy.
Clinical cancer research : an official journal of the American Association for Cancer Research 2002;8(9):2775-81.
2001: Steven J O'Day; Peter D Boasberg; Timothy S Kristedja; Maureen Martin; He-Jing Wang; Patricia Fournier; M Cabot; Michael W DeGregorio; Guy Gammon
High-dose tamoxifen added to concurrent biochemotherapy with decrescendo interleukin-2 in patients with metastatic melanoma.
Cancer 2001;92(3):609-19.
1999: Steven J O'Day; Guy Gammon; Peter D Boasberg; M A Martin; Timothy S Kristedja; Mingzhou Guo; S Stern; S Edwards; Patricia Fournier; M Weisberg; M Cannon; N W Fawzy; T D Johnson; Richard Essner; Leland J Foshag; Donald L Morton
Advantages of concurrent biochemotherapy modified by decrescendo interleukin-2, granulocyte colony-stimulating factor, and tamoxifen for patients with metastatic melanoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999;17(9):2752-61.